MedChemComm p. 963 - 968 (2018)
Update date:2022-08-02
Topics:
Pippione, Agnese C.
Sainas, Stefano
Federico, Antonella
Lupino, Elisa
Piccinini, Marco
Kubbutat, Michael
Contreras, Jean-Marie
Morice, Christophe
Barge, Alessandro
Ducime, Alex
Boschi, Donatella
Al-Karadaghi, Salam
Lolli, Marco L.
NF-κB-inducing kinase (NIK), an oncogenic drug target that is associated with various cancers, is a central signalling component of the non-canonical pathway. A blind screening process, which established that amino pyrazole related scaffolds have an effect on IKKbeta, led to a hit-to-lead optimization process that identified the aminopyrazole 3a as a low μM selective NIK inhibitor. Compound 3a effectively inhibited the NIK-dependent activation of the NF-κB pathway in tumour cells, confirming its selective inhibitory profile.
View MoreWuhan Yitongtai Science and Technology Co.,Ltd.
Contact:+86-27-88933550
Address:27th Fl. Bldg. 1, Shuian International Mansion, Heping Ave, Wuhan, Hubei, China
Jinan Hongfangde Pharmatech Co.LTD
Contact:0531-88870908
Address:F Bldg,750#,Shunhua Rd,New&High-tech Zone,Jinan,Shandong,China 250101
Suzhou Lixin Pharmaceutical Co., Ltd.
Contact:86-512-88169812
Address:21 Tangxi Road, Suzhou New District, Suzhou 215151
Zhejiang Haizhou Pharmaceutical Co., Ltd.
website:https://www.haizhoupharma.com/
Contact:+86 576 88221016
Address:No. 19, Donghai 5th Avenue, Yanhai Industrial Zone, Linhai, Zhejiang, China
Xi'an North Information Industry Co., Ltd. Weilv Chemical Department
Contact:+86-29-88156413
Address:Jixiang Road 99 Xi'an Shaanxi Province
Doi:10.1021/ja01513a058
(1959)Doi:10.1016/j.poly.2004.06.014
(2004)Doi:10.1007/s11094-020-02172-4
(2020)Doi:10.1021/ja00395a071
(1981)Doi:10.1055/s-1980-29275
(1980)Doi:10.1002/ejoc.200400291
(2004)